China joins with Philips for biomarker/Dx tests research:
This article was originally published in Clinica
China's Institute of Health Sciences (IHS) and Royal Philips Electronics signed a memorandum of understanding on August 29 to establish a joint molecular medicine research laboratory. The lab, which will be located at the IHS in Shanghai, will focus on biomarker discovery and the development of next-generation in vitro diagnostic tests, with the aim of developing new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment. The IHS is part of the Shanghai Institutes for Biological Sciences (SIBS).
You may also be interested in...
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.